ANT 1403
Alternative Names: ANT-1403Latest Information Update: 18 May 2020
At a glance
- Originator Anterios
- Class Biological factors; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperhidrosis
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 31 Jul 2013 Anterios completes a phase II trial in Hyperhidrosis in USA (NCT01799824)
- 21 Jun 2013 Anterios completes enrolment in its phase II trial for Hyperhidrosis in USA (NCT01799824)